trending Market Intelligence /marketintelligence/en/news-insights/trending/uYDbfP4hghjEYCLOL04j4w2 content esgSubNav
In This List

InVivo Therapeutics director to resign

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


InVivo Therapeutics director to resign

InVivo Therapeutics Holdings Corp. said that Jeffrey Hatfield will resign from the board and its audit and compensation committees, effective Dec. 31.

Hatfield's resignation is not due to any conflict or disagreement with the company or its board, InVivo Therapeutics said in a Dec. 10 regulatory document.

InVivo Therapeutics is a research and clinical-stage biomaterials and biotechnology company that develops scaffolding devices for spinal cord injuries.